Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

用于莱姆病快速血清诊断的芯片即时检测实验室

• 批准号: 9052111
• 负责人: Maria Gomes-Solecki
• 金额: $ 100万
• 依托单位: IMMUNO TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-03 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9052111
• 关键词: Affect; Aftercare; Algorithms; Antibiotics; Antibodies; Antigens; Area; Arthritis; Bedside Testings; Biological Assay; Biological Markers; Blood; Blood Volume; Borrelia burgdorferi; Caring; Centers for Disease Control and Prevention (U.S.); Collaborations; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic tests; Disease; Disease Outcome; Disease Progression; Early Diagnosis; Early treatment; Enzyme-Linked Immunosorbent Assay; Extramural Activities; Fingers; Health; Heart; Human; In Vitro; Injury; Joints; Laboratories; Lead; Letters; Lyme Disease; Microfluidics; Nervous system structure; Phase; Refractory; Reproducibility; Running; Sensitivity and Specificity; Serodiagnoses; Serological; Serum; Skin; Staging; Symptoms; Syndrome; System; Technology; Testing; Time; United States; Validation; Vector-transmitted infectious disease; base; body system; cost; cross reactivity; design; improved; micro-total analysis system; outcome forecast; performance tests; point of care; polypeptide; prevent; prototype; standard of care; validation studies

DESCRIPTION: Caused by Borrelia burgdorferi, Lyme disease (LD) can affect the skin, heart, joints or nervous system leading to an array of largely non-specific symptoms that overlap with those of other debilitating illnesses. Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic-refractory arthritis or Post- Treatment Lyme disease Syndrome (PTLDS). Early diagnosis and treatment is key to improving disease outcomes. Current assays do not discriminate between early and late stages of the disease and cannot predict prognosis. We propose to use ultrasensitive microfluidics technology to develop the first quantitative rapid lab-on-a-chip point of care (POC) assay for the serodiagnosis of Lyme disease. The proposed POC test will provide sensitive and definitive detection and differentiation of early- and late- stage Lyme disease in a single test. It is a versatile and informative first-tier assay which can evolve to replace the current bi-serologic two-tier standard of care.

描述：莱姆病 (LD) 由伯氏疏螺旋体引起，会影响皮肤、心脏、关节或神经系统，导致一系列很大程度上非特异性的症状，这些症状与其他使人衰弱的疾病的症状重叠。疾病进展可能导致预后不良的病症，例如抗生素难治性关节炎或治疗后莱姆病综合征（PTLDS）。早期诊断和治疗是改善疾病结果的关键。目前的检测不能区分疾病的早期和晚期，也不能预测预后。我们建议使用超灵敏微流体技术开发第一个用于莱姆病血清诊断的定量快速芯片实验室护理点 (POC) 测定。拟议的 POC 测试将在一次测试中提供早期和晚期莱姆病的灵敏且明确的检测和区分。它是一种多功能且信息丰富的一级检测，可以发展以取代当前的双血清学二级标准 的照顾。

项目成果

Borrelia burgdorferi BBI39 Paralogs, Targets of Protective Immunity, Reduce Pathogen Persistence Either in Hosts or in the Vector.

伯氏疏螺旋体 BBI39 旁系同源物是保护性免疫的目标，可减少宿主或载体中病原体的持续存在。

• 发表时间: 2017-03-15
• 作者: Singh, Preeti;Verma, Deepshikha;Backstedt, Brian T;Kaur, Simarjot;Kumar, Manish;Smith, Alexis A;Sharma, Kavita;Yang, Xiuli;Azevedo, José F;Gomes;Buyuktanir, Ozlem;Pal, Utpal
• 通讯作者: Pal, Utpal